SOTIO Presents New Data on SOT201, VICTORIA-01, and BOXR CAR-T at 2024 SITC Meeting

PRAGUE & BASEL, Switzerland & BOSTON--(BUSINESS WIRE)--SOTIO Biotech, an immuno-oncology firm owned by PPF Group, has unveiled promising data for its novel PD-1-targeting immunocytokine, SOT201, and introduced new enhancements in its BOXR cell therapy platform. These developments will be featured in three posters at the upcoming 2024 Society for Immunotherapy of Cancer Meeting, scheduled from November 6-10 in Houston, Texas.

SOT201 is an advanced PD-1-targeted and cis-acting IL-15 agonist, engineered to selectively activate PD-1+ CD8+ T cells, thereby producing robust anti-tumor responses and rejuvenating exhausted CD8+ T cells in both PD-1 sensitive and resistant tumors. The VICTORIA-01 study, a Phase 1, open-label, dose escalation trial, is currently underway to evaluate the safety, tolerability, and preliminary efficacy of SOT201 as a monotherapy in adults with advanced unresectable or metastatic solid tumors (NCT06163391). This trial is actively enrolling participants across six locations in the U.S., Belgium, Spain, and the Czech Republic. To date, four patients have been treated with the therapy, all of whom have tolerated it well.

Dr. Martin Steegmaier, Chief Scientific Officer of SOTIO, commented on the promising attributes of SOT201, stating, "SOT201 has shown a remarkable ability to reinvigorate exhausted tumoral CD8+ T cells with significant cytotoxicity and minimal cellular exhaustion when compared to the related cytokine PD1-IL2v. These findings highlight SOT201’s reduced off-target interactions and sustained anti-tumor efficacy in vivo, showcasing its potential to overcome the current limitations of anti-PD-1 therapies as we continue to enroll patients in the VICTORIA-01 study."

Additionally, SOTIO Biotech will present a preclinical study focusing on a chimeric PGC-1α transgene designed to enhance CAR T cell function. The study demonstrated that chimeric PGC-1α transduced cells had fewer dysfunctional mitochondria and improved glucose uptake compared to control CAR T cells. Dr. Steegmaier added, "The chimeric PGC-1α significantly boosted CAR T cell anti-tumor efficacy without causing significant toxicity, indicating that the co-expression of CAR and chimeric PGC-1α could be a promising strategy to improve CAR T cell efficacy in solid tumors."

SOTIO Biotech is committed to advancing cancer immunotherapies and translating groundbreaking science into tangible patient benefits. The company’s pipeline includes SOT102, a next-generation Claudin-18.2-targeted antibody-drug conjugate that began clinical trials in 2022, and BOXR1030, a metabolically-enhanced CAR-T cell therapy targeting GPC3-expressing tumors. The pipeline also boasts other promising candidates nearing clinical stages, including SOT201. SOTIO Biotech is a member of the PPF Group, and more information about the company can be found on their website.

Note: Presentation materials from the 2024 Society for Immunotherapy of Cancer Meeting will be available on November 10, after the conclusion of the conference.